446 related articles for article (PubMed ID: 18762907)
1. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
Targher G; Marra F; Marchesini G
Diabetologia; 2008 Nov; 51(11):1947-53. PubMed ID: 18762907
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.
Targher G; Chonchol M; Miele L; Zoppini G; Pichiri I; Muggeo M
Semin Thromb Hemost; 2009 Apr; 35(3):277-87. PubMed ID: 19452403
[TBL] [Abstract][Full Text] [Related]
3. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk.
Pacifico L; Nobili V; Anania C; Verdecchia P; Chiesa C
World J Gastroenterol; 2011 Jul; 17(26):3082-91. PubMed ID: 21912450
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.
Targher G; Arcaro G
Atherosclerosis; 2007 Apr; 191(2):235-40. PubMed ID: 16970951
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?
Ahmed MH; Barakat S; Almobarak AO
J Obes; 2012; 2012():483135. PubMed ID: 23320150
[TBL] [Abstract][Full Text] [Related]
6. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
Santos RD; Valenti L; Romeo S
Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers.
Edens MA; Kuipers F; Stolk RP
Obes Rev; 2009 Jul; 10(4):412-9. PubMed ID: 19413701
[TBL] [Abstract][Full Text] [Related]
8. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
9. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
Byrne CD
Proc Nutr Soc; 2013 Nov; 72(4):412-9. PubMed ID: 23668723
[TBL] [Abstract][Full Text] [Related]
10. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?
Targher G; Chonchol M; Pichiri I; Zoppini G
J Endocrinol Invest; 2011; 34(7):544-51. PubMed ID: 21427524
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.
Bonora E; Targher G
Nat Rev Gastroenterol Hepatol; 2012 May; 9(7):372-81. PubMed ID: 22565095
[TBL] [Abstract][Full Text] [Related]
12. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
[TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
Kim HS; Cho YK
Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients.
Mikolasevic I; Racki S; Zaputovic L; Lukenda V; Milic S; Orlic L
Med Hypotheses; 2014 Feb; 82(2):205-8. PubMed ID: 24365277
[TBL] [Abstract][Full Text] [Related]
15. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.
Stepanova M; Younossi ZM
Clin Gastroenterol Hepatol; 2012 Jun; 10(6):646-50. PubMed ID: 22245962
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease and cardiovascular disease.
Hyogo H; Chayama K; Yamagishi S
Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
[TBL] [Abstract][Full Text] [Related]
17. [Fatty liver and global cardiometabolic risk].
Szollár L
Orv Hetil; 2010 Nov; 151(47):1946-50. PubMed ID: 21071306
[TBL] [Abstract][Full Text] [Related]
18. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis.
Pacana T; Fuchs M
Clin Liver Dis; 2012 Aug; 16(3):599-613. PubMed ID: 22824483
[TBL] [Abstract][Full Text] [Related]
19. Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis.
Sánchez-Jiménez BA; Brizuela-Alcántara D; Ramos-Ostos MH; Alva-López LF; Uribe-Esquivel M; Chávez-Tapia NC
Alcohol; 2018 Jun; 69():63-67. PubMed ID: 29660603
[TBL] [Abstract][Full Text] [Related]
20. NAFLD and cardiovascular diseases: a clinical review.
Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
